Abstract: Presented herein are methods and systems for generating intermediate code files adjusted to prevent return oriented programming exploitation, comprising receiving compiled intermediate code file(s) comprise a plurality of routines and adjusting them prior to generation of a respective executable file for execution by one or more processor. The adjusting comprising analyzing a symbol table of the intermediate code file(s) to identify a beginning address of each of the routines, analyzing each of the routines to identify indirect branch instructions in the routines, and replacing each detected indirect branch instruction with invocation of a verification code segment configured to verify that the respective indirect branch instruction points to the beginning address of one of the routines. In runtime, the verification code segment causes the processor(s) to initiate one or more predefined actions in case the indirect branch instruction isn't pointing to the beginning address of one of the plurality of routines.

Abstract: A pharmaceutical composition comprising Ivermectin-HPBCD complexed adjuvant formulated for injection or infusion or instillation into a subject, as well as methods for formulating and using the same. The adjuvant composition of the invention in its preferred form comprises an ivermectin-HPBCD complex wherein 1 to 3 grams of the complex is dissolved in 1 ml Tween80 combined with 9 ml sterile distilled water at a pH 6.4. Composition of the present instant invention comprising ivermectin-HPBCD complexed adjuvant formulated for administration via injection or infusion or instillation to a subject find use in treatment and/or prevention of cancer.

Abstract: A method of applying tumor treating fields to a torso of a subject's body, the method including: locating a first transducer at a first location of the subject's body, the first location being on the torso of the subject's body; locating a second transducer at a second location of the subject's body, the second location being below the torso of the subject's body; and inducing an electric field between at least part of the first transducer and at least part of the second transducer.

Abstract: A process and an installation for producing a yarn in accordance with an airjet-spinning method. A carded fibre sliver is subjected to more than three-fold drawing without levelling at a carding machine and deposited in a can (C). At least nine fibre slivers are fed draftfree from cans (C) to a draw frame and subjected to at least 8.5-fold drawing to form a fibre sliver and deposited in a can (C1). The fibre sliver in the cans (C1) is then fed to a spinning station of an airjet-spinning machine.

Abstract: The present invention relates to the unexpected discovery of a new strain of yeast, dubbed GY7B, which is related to, but genetically and phenotypically distinct from, Lachancea thermotolerans. The invention provides methods of brewing sour beer using GY7B, wherein the methods do not require use of lactic acid or lactic acid producing bacteria.

Abstract: A robot device includes a first link and a second link coupled to the first link via an elbow. One or more of the first link or the second link rotates about an axis of the elbow. The robot device further includes a generator disposed in the elbow. The generator is configured to generate electrical power based on relative angular mechanical movement associated with the elbow. The robot device further includes an end effector configured to transport a substrate within a substrate processing system. The end effector is disposed at a distal end of the second link. The end effector is to receive the electrical power generated by the generator.

Abstract: An apparatus for generating an output oscillator signal is provided. The apparatus includes a deviation determining circuitry configured to generate a deviation signal based on a first comparison signal and a second comparison signal. Further, the apparatus includes a first oscillator configured to generate the output oscillator signal based on the deviation signal and a second oscillator signal from a second, resonator-based oscillator. The first comparison signal is based on the second oscillator signal or the output oscillator signal. The second oscillator signal has a frequency of at least 1 GHz. The second comparison signal is based on a third oscillator signal from a third oscillator. The third oscillator signal has a frequency lower than 1 GHz.

Abstract: The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.

Abstract: A computer-implemented method includes receiving permission data from an application server. The permission data is for an account to access a software application of a plurality of software applications, and the application server is configured to provide the software application. Responsive to receiving the permission data from the application server, storing the permission data in a native database. Receiving a request to grant the account access to the software application. Determining whether the database stores the permission data for the account to access the software application. In response to determining that the database stores the permission data, granting access to the account to access the software application.

Abstract: Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 5 or 10 mg of macrocyclic lactone to 1 mL of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.

Abstract: Formulation systems usable for fabricating a three-dimensional object made of a polyamide-containing material, by three-dimensional 3D inkjet printing, and methods and systems utilizing same, are provided. The formulation systems are formed of at least a first and second model formulations containing a lactam and a catalyst for inducing anionic ring opening polymerization of the lactam in the first formulation, and an activator for promoting anionic ring opening polymerization of the lactam in the second formulation, and are further characterized as: including in the first and/or second formulation a compound capable of increasing a rate of said polymerization upon exposure to said curing energy; including as an activator a lactam-blocked polyisocyanate; and/or as including in the first model formulation at least one material capable of reducing a melting point of said first model formulation. Formulation systems usable at a selected ratio are also provided.

Abstract: A topical solubilized ivermectin pharmaceutical composition for the treatment and/or prevention of inflammatory skin conditions is disclosed herein. The topical solubilized ivermectin pharmaceutical composition comprises an ivermectin and a cyclodextrin. Particularly, ivermectin is combined with cyclodextrin to form an ivermectin-cyclodextrin complex solubilized in a Tween80-water solution up to a 30% by weight of solution. The present invention features a formulation of Ivermectin-cyclodextrin complex solubilized in a Tween80-water solution incorporated into lotion or cream or gel base that is highly effective in the treatment inflammatory skin conditions at a concentration of, in some embodiments, 0.125% to 5% ivermectin by weight.

Abstract: Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Formula 1), or a pharmaceutically acceptable salt thereof. Further provided are pharmaceutical formulations and solid forms of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, and their use in the treatment of congenital adrenal hyperplasia (CAH).

Abstract: The basis to develop a cosmetic and pharmaceutical composition based on a combinatorial derivative of quercetin in the form of nanoparticles (liposomes) for the treatment of atherosclerosis and its complications, as well as hypertension, for rejuvenating the body and healing wounds. The problem is solved by obtaining a cosmetic and pharmaceutical composition based on a combinatorial quercetin derivative, characterized in that the modified combinatorial quercetin derivative is represented as a combinatorial library (mixture) of quercetin derivatives obtained by simultaneous combinatorial modification of quercetin with at least two alkylating and acylating modifiers in the combinatorial reaction synthesis to obtain the maximum number of different derivatives of quercetin, and as biologically active substances, a whole combinatorial mixture of quercetin derivatives is used without separation into individual components to create cosmetic and pharmaceutical compositions.

Abstract: Presented herein are methods and systems for generating intermediate code files adjusted to prevent return oriented programming exploitation, comprising receiving compiled intermediate code file(s) comprise a plurality of routines and adjusting them prior to generation of a respective executable file for execution by one or more processor. The adjusting comprising analyzing a symbol table of the intermediate code file(s) to identify a beginning address of each of the routines, analyzing each of the routines to identify indirect branch instructions in the routines, and replacing each detected indirect branch instruction with invocation of a verification code segment configured to verify that the respective indirect branch instruction points to the beginning address of one of the routines. In runtime, the verification code segment causes the processor(s) to initiate one or more predefined actions in case the indirect branch instruction isn't pointing to the beginning address of one of the plurality of routines.

Abstract: In one aspect of the present disclosure, an object monitoring system for a secured area is provided. The object monitoring system includes an image sensor operable to capture an image of the secured area and a memory configured to store a machine learning algorithm trained to identify a vehicle in the secured area, the machine learning algorithm including feature maps of training images captured by the image sensor. The object monitoring system further includes a processor operably coupled to the image sensor and the memory, the processor configured to calculate a feature descriptor of the image and to utilize the machine learning algorithm and the image of the secured area to determine whether a vehicle is present in the secured area by determining a correlation between the feature descriptor of the image and the feature maps of the training images.

Abstract: Field of application: the invention relates to veterinary medicine and, in particular, to vaccinology and pharmacy, and is intended for the prevention and treatment of infectious and other diseases of humans and animals, where low allergenic low reactogenic vaccination is used. The essence of the invention: developed vaccines with increased immunogenicity, low allergenicity and reactogenicity, containing antigen/toxin and adjuvant, wherein that they contain vaccine antigen/toxin inactivated by electromagnetic radiation in the ultraviolet and visible regions of the spectrum in the presence of a solution of photosensitizer and salts of divalent metals, and then covalently modified according to the residues of amino groups and hydroxyls groups of antigen/toxin available for modification, at least two modifying agents at the same time in terms of 0.01-10.0% of the mass concentration of the antigen/toxin protein, and as an adjuvant it contains hydrosol hydroxide ferric chloride.

Abstract: A computer-implemented method for adaptive behavioral training includes presenting a first visual training area to a user in a visual presentation. The visual presentation is displayed in a coordinate space and the first visual training area is defined by a first set of coordinates in the coordinate space. Measurement data is collected while the first visual training area is presented to the user. This measurement data comprises eye tracking measurement data indicating the user's gaze with respect to the first visual training area. Based on the measurement data, a second visual training area is selected. This second visual training area is defined by a second set of coordinates in the coordinate space that are different than the first set of coordinates. The second visual training area is then presented to the user in the visual presentation.

Abstract: A movable barrier operator system is provided that includes a moving-barrier imminent motion notification apparatus, a motor, a controller, and communication circuitry configured to communicate with a remote control. In response to the communication circuitry receiving a communication from the remote control, the controller causes the motor to change the state of the movable barrier and additionally operate the moving-barrier imminent motion notification apparatus upon a determination of the remote control being beyond a physical proximity of a location associated with the movable barrier operator system. Upon a determination that the remote control is within the physical proximity, the controller refrains from operation of the moving-barrier imminent motion notification apparatus.

Abstract: Methods, apparatuses, or computer program products are disclosed providing for the dynamic generation and traversal of object dependency data structures. Examples enable generation of service dependency work graph structures for service dependencies associated with one or more services and dynamic replacement of service instances based upon traversal of the service dependency work graph data structures.